Skip to Content

Intercept Pharmaceuticals, Inc.

Merger

  • Date:
  • 9/26/2023
  • Company Name:
  • Intercept Pharmaceuticals, Inc.
  • Stock Symbol:
  • ICPT
  • Company Name - Buyer:
  • Alfasigma S.p.A.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 9/27/2023

Case Finder

Locate any case using the tools below.

NEW YORK, September 26, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Alfasigma S.p.A. (“Alfasigma”).

On September 26, 2023, Intercept announced that it had entered into an agreement to be acquired by Alfasigma in an all-cash deal. Pursuant to the merger agreement, Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The transaction price represents an 82% premium to Intercept’s closing price on September 25, 2023. The deal is expected to close by the end of 2023.

Bragar Eagel & Squire is concerned that Intercept's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Intercept's stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Intercept Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: